Clear Street initiated coverage of LB Pharmaceuticals (NASDAQ: LBRX) with a “buy” rating and price target of $45.00. The stock closed at $28.33 on May 26th.
LB Pharmaceuticals is a late-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the opportunity to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.
LB-102, an analog of long-established, marketed amisulpride (>2M prescriptions/month), benefits from a strongly validated biology, while highly compelling P2 data—showing robust efficacy, cognitive benefits, and limited key toxicities that constrain long-term use of marketed agents. Following the precedent set by Vraylar ($4.3B 2028E sales, Factset consensus) and Caplyta ($4.6B 2031E sales, Factset consensus), LB-102 is also being developed in bipolar disorder (P2 ongoing; data in 1Q28) and adjunctive MDD (P2 initiation in early 2027; data in 1H29), both representing global opportunities and incremental upside beyond our current valuation. Moreover, LB-102’s differentiated biology supports expansion into additional indications, including negative symptoms of schizophrenia and Alzheimer’s disease–related psychosis and agitation, adding optionality to the story.
“Our 12-month PT of $45 per share is based on a DCF analysis employing an 18% discount rate and 0% terminal growth,” writes Kaveri Pohlman, PhD, a Managing Director and Senior Equity Analyst covering Biotechnology at Clear Street. “While LBRX’s estimated WACC is ~10% (FactSet), we apply a materially higher rate to reflect the elevated, modality-wide risk inherent in neuropsychiatric drug development, despite LBRX’s late-stage profile. The 0% terminal growth assumption further captures the company’s concentration on a single drug (LB-102, with multiple formulations) and the absence of concrete plans to diversify the pipeline in a manner that could support a more durable long-term growth.”
